Cellectis announces the redemption of the bonds redeemable into shares subscribed by the FSI and Pierre Bastid for a total of €50 million

Regulatory News:

Cellectis (Paris:ALCLS) (Alternext: ALCLS), the French genome engineering specialist, is announcing the redemption of all the bonds redeemable into shares (ORA) issued on November 3rd, 2011 to the FSI and Pierre Bastid for a total amount of €50 million and the corresponding interest.

Under the terms of the bonds redeemable into shares, the Board of directors has acknowledged their automatic early redemption into a total of 6,250,000 Company shares, at a price of €8 per share of a nominal value of €0.05, or an issue premium of €7.95 per share. This redemption follows the average closing share price (volume-weighted) exceeding €8 for three consecutive trading days. The volume-weighted average closing price recorded for the Company's shares between February 1^st and 3^rd, 2012 was €8.06.

The Board of Directors, acting upon the delegation given by the general shareholders meeting of October 28^th, 2011, has decided to issue to the FSI and Pierre Bastid, on an equal basis, a total of 54,660 additional new shares with a nominal value of €0.05 per share at a price of €7.8392, giving a premium of €7.7892 per share. This operation represents a subscription of a total of €428,490.672 euros (including issue premium). By offsetting the debt, it will make it possible to clear the interest owed by the Company to the FSI and Pierre Bastid in relation to the bonds redeemable into shares.

Following this principal and interest-based redemption, the total number of outstanding shares is 20,434,714. The FSI and Pierre Bastid each hold 3,152,330 shares, representing approximately 15.4% of Cellectis capital.

About the FSI

The FSI (Fonds Stratégique d'Investissement or Strategic Investment Fund) is a limited liability company owned by the Caisse des Dépôts (51%) and by the French state (49%). It is a prudent investor that makes equity investments to take a minority interest in French companies implementing projects that create value and competitiveness for the economy.

For further information: www.fonds-fsi.fr.

About Pierre Bastid

Pierre Bastid is a French industrialist, and former Chairman and CEO of Converteam, which he bought from Alstom in 2005 with the support of investment funds and sold to General Electric in September 2011. Pierre Bastid will now focus on private investment, targeting primarily high-potential companies in emerging industries.

About Cellectis

Cellectis improves life quality by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at www.cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to the public, an offer to subscribe, or the solicitation of the public in view of an offer of securities to the public.

Contacts:

For further information, please contact:
Cellectis
Philippe Valachs, [phone]
Company Secretary
[e-mail]
or
Marc Le Bozec, [phone]
Chief Financial Officer
[e-mail]
or
Calyptus
Alexis Breton / Cyril Combe, [phone]
[e-mail]